x NoneEntity Type
0001539029
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Clearside Biomedical, Inc.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Clearside Biomedical, Inc. 
Street Address 1Street Address 2
 900 NORTH POINT PARKWAY SUITE 200
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 ALPHARETTA GEORGIA 30005 678-270-3631 



3. Related Persons
Last NameFirst NameMiddle Name
LasezkayGeorge
Street Address 1Street Address 2
c/o Clearside Biomedical, Inc.900 North Point Parkway, Suite 200
CityState/Province/CountryZIP/Postal Code
AlpharettaGEORGIA30005
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
DeignanCharlesA.
Street Address 1Street Address 2
c/o Clearside Biomedical, Inc.900 North Point Parkway, Suite 200
CityState/Province/CountryZIP/Postal Code
AlpharettaGEORGIA30005
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
HumphriesWilliamD.
Street Address 1Street Address 2
c/o Clearside Biomedical, Inc.900 North Point Parkway, Suite 200
CityState/Province/CountryZIP/Postal Code
AlpharettaGEORGIA30005
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
CroarkinRichard
Street Address 1Street Address 2
c/o Clearside Biomedical, Inc.900 North Point Parkway, Suite 200
CityState/Province/CountryZIP/Postal Code
AlpharettaGEORGIA30005
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
EdwardsJeffreyL.
Street Address 1Street Address 2
c/o Clearside Biomedical, Inc.900 North Point Parkway, Suite 200
CityState/Province/CountryZIP/Postal Code
AlpharettaGEORGIA30005
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
ShafferChristyL.
Street Address 1Street Address 2
c/o Clearside Biomedical, Inc.900 North Point Parkway, Suite 200
CityState/Province/CountryZIP/Postal Code
AlpharettaGEORGIA30005
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
ThorpClayB.
Street Address 1Street Address 2
c/o Clearside Biomedical, Inc.900 North Point Parkway, Suite 200
CityState/Province/CountryZIP/Postal Code
AlpharettaGEORGIA30005
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  x Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2019-11-26 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests x Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities o Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
  
(Associated) Broker or Dealer o None(Associated) Broker or Dealer CRD Number o None
  
Street Address 1Street Address 2
  
City State/Province/CountryZIP/Postal Code
   
State(s) of Solicitation o All States
 
 



13. Offering and Sales Amounts
Total Offering Amount $ 3349999 USD o Indefinite
Total Amount Sold $ 3349999 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
  


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 3


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024 Haga Click aquí para más Gráficas Clearside Biomedical.
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024 Haga Click aquí para más Gráficas Clearside Biomedical.

Noticias sobre Clearside Biomedical, Inc. CLSD

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board
Jueves 11 de Julio 2024 (6 días hace) • GlobeNewswire Inc.
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
Jueves 27 de Junio 2024 (3 semanas hace) • GlobeNewswire Inc.
Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
Miércoles 12 de Junio 2024 (1 mes hace) • GlobeNewswire Inc.
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®
Martes 21 de Mayo 2024 (2 meses hace) • GlobeNewswire Inc.
Form S-8 - Securities to be offered to employees in employee benefit plans
Viernes 10 de Mayo 2024 (2 meses hace) • Edgar (US Regulatory)
Form 8-K - Current report
Jueves 9 de Mayo 2024 (2 meses hace) • Edgar (US Regulatory)
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
Jueves 9 de Mayo 2024 (2 meses hace) • GlobeNewswire Inc.
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
Miércoles 8 de Mayo 2024 (2 meses hace) • GlobeNewswire Inc.
Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024
Martes 30 de Abril 2024 (3 meses hace) • GlobeNewswire Inc.
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
Martes 16 de Abril 2024 (3 meses hace) • GlobeNewswire Inc.
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Martes 2 de Abril 2024 (3 meses hace) • GlobeNewswire Inc.
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
Lunes 18 de Marzo 2024 (4 meses hace) • GlobeNewswire Inc.

Más de Clearside Biomedical, Inc. Artículos de Noticias